The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Lifetime Risks of Common Cancers Among Retinoblastoma Survivors
Abstract
BACKGROUND: Compared with the general population, carriers of germline mutations in RB1 who survive retinoblastoma (i.e., hereditary retinoblastoma survivors) are at increased risk of early-onset second cancers, particularly sarcomas, brain tumors, and melanoma. However, their risks for the epithelial cancers that commonly occur after age 50 years are not known. METHODS: We used hospital records to identify British retinoblastoma survivors born between 1873 and 1950, a period when few British retinoblastoma patients received high-dose radiotherapy. Cancers and deaths were identified by linkage with national registration records. All statistical tests were two-sided. RESULTS: We could trace the cancer histories of 144 survivors of hereditary retinoblastoma. From age 25 to age 84, there were 58 subsequent cancers, for a cumulative cancer incidence of 68.8% (95% confidence interval [CI] = 48.0% to 87.4%) and a cumulative cancer mortality of 56.3% (95% CI = 40.5% to 73.3%). Only eight of the 58 cancers were of bone or soft tissue, in marked contrast to findings from contemporary studies of American patients treated with external beam radiotherapy, among whom most second tumors are sarcomas. Compared with the general population, hereditary retinoblastoma survivors had higher mortality from lung cancer (standardized mortality ratio [SMR] = 7.01, 95% CI = 3.83 to 11.76), bladder cancer (SMR = 26.31, 95% CI = 8.54 to 61.41), and all other epithelial cancers combined (SMR = 3.29, 95% CI = 1.64 to 5.89). The overall standardized mortality ratio for epithelial cancer was inversely proportional to the approximate square of age (exponent of age = -2.1, 95% CI = -3.6 to -0.7), declining from 11.32 (95% CI = 4.15 to 24.64) at age 25-44 to 2.83 (95% CI = 1.04 to 6.16) at age 65-84. CONCLUSIONS: Survivors of hereditary retinoblastoma who are not exposed to high-dose radiotherapy have a high lifetime risk of developing a late-onset epithelial cancer. Most of the excess cancer risks in hereditary retinoblastoma survivors might be preventable by limiting exposures to DNA damaging agents (radiotherapy, tobacco, and UV light).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Cited by
Kleinerman, R. A., Tucker, M. A., Tarone, R. E., Abramson, D. H., Seddon, J. M., Stovall, M., Li, F. P., & Fraumeni, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.054 · Cited by 487
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-up
Marees, T., Moll, A. C., Imhof, S. M., de Boer, M. R., Ringens, P. J., & van Leeuwen, F. E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn394 · Cited by 286
Time since first sexual intercourse and the risk of cervical cancer
Plummer, M., Peto, J., Franceschi, S., & ; on behalf of the International Collaboration of Epidemiological Studies of Cervical Cancer (2012) · International Journal of Cancer · doi:10.1002/ijc.26250 · Cited by 172
Self-citationAt-Risk Populations for Osteosarcoma: The Syndromes and Beyond
Calvert, G. T., Randall, R. L., Jones, K. B., Cannon-Albright, L., Lessnick, S., & Schiffman, J. D. (2012) · Sarcoma · doi:10.1155/2012/152382 · Cited by 90
Metadata
- Authors
- Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03-02
- Volume
- 96
- Issue
- 5
- Pages
- 357-363
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2164157837
- Cited by
- 312
- References
- 4
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lifetime Risks of Common Cancers Among Retinoblastoma Survivors. https://app.cochat.ai/papers/10.1093/jnci/djh058
- The paper
- Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J. (2004). Lifetime Risks of Common Cancers Among Retinoblastoma Survivors. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.